Legis Daily

STOP Fentanyl Act of 2021

USA117th CongressHR-2366| House 
| Updated: 10/19/2021
Ann M. Kuster

Ann M. Kuster

Democratic Representative

New Hampshire

Cosponsors (13)
Tim Ryan (Democratic)Lisa Blunt Rochester (Democratic)David J. Trone (Democratic)Jimmy Panetta (Democratic)Debbie Dingell (Democratic)Madeleine Dean (Democratic)Paul Tonko (Democratic)Don Bacon (Republican)Joseph D. Morelle (Democratic)Dean Phillips (Democratic)Theodore E. Deutch (Democratic)Peter Welch (Democratic)Teresa Leger Fernandez (Democratic)

Crime and Federal Government Surveillance Subcommittee, Health Subcommittee, Judiciary Committee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Support, Treatment, and Overdose Prevention of Fentanyl Act of 2021 or the STOP Fentanyl Act of 2021 This bill addresses data collection, treatment, harm reduction, and other issues related to substance misuse and addiction. It particularly focuses on opioids, fentanyl, and related substances. Specifically, the bill expands surveillance of fentanyl and related substances. This includes establishing a pilot program to screen for contaminants in illicit drugs and a grant program to collect data on fentanyl-involved overdoses. The bill also specifies requirements concerning the collection and use of information about drugs seized by law enforcement. Additionally, the bill establishes and modifies requirements to increase access to treatment and prevention services. For example, the Bureau of Prisons must make certain services, including medication-assisted treatments, available to individuals in its custody. The bill also repeals a provision that requires dependence on opioids for at least one year before an individual may be admitted to certain treatment programs; allows providers to prescribe medications to treat substance use disorders following a telehealth evaluation; creates grant programs for treatment and harm reduction activities; and addresses issues pertaining to opioid overdose reversal drugs. Furthermore, the bill limits civil and criminal liability under specified laws for individuals who administer opioid overdose reversal drugs to an individual who reasonably appears to be experiencing an overdose, as well as for individuals who seek medical attention for themselves or on behalf of another for a drug overdose. The bill also requires multiple reports, including a report by the Department of State on foreign sources of certain drugs.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 5, 2021
Introduced in House
Apr 5, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 13, 2021
Referred to the Subcommittee on Health.
Apr 29, 2021

Latest Companion Bill Action

S 117-1457
Introduced in Senate
Oct 19, 2021
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
  • April 5, 2021
    Introduced in House


  • April 5, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 13, 2021
    Referred to the Subcommittee on Health.


  • April 29, 2021

    Latest Companion Bill Action

    S 117-1457
    Introduced in Senate


  • October 19, 2021
    Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

Health

Related Bills

  • S 117-1457: STOP Fentanyl Act of 2021
American SamoaCardiovascular and respiratory healthCivil actions and liabilityCongressional oversightCorporate finance and managementCorrectional facilities and imprisonmentCriminal investigation, prosecution, interrogationCriminal justice information and recordsCriminal procedure and sentencingCustoms enforcementDrug, alcohol, tobacco useDrug safety, medical device, and laboratory regulationDrug therapyDrug trafficking and controlled substancesEmergency medical services and trauma careFederal preemptionGovernment information and archivesGovernment studies and investigationsHealth care costs and insuranceHealth care coverage and accessHealth information and medical recordsHealth programs administration and fundingHealth promotion and preventive careHealth technology, devices, suppliesHIV/AIDSHome and outpatient careIndian social and development programsInfectious and parasitic diseasesInflation and pricesInternet and video servicesInternet, web applications, social mediaLaw enforcement administration and fundingLaw enforcement officersManufacturingMarketing and advertisingMedical researchMental healthMinority healthNorthern Mariana IslandsPerformance measurementPostal servicePrescription drugsResearch administration and fundingResearch and developmentRural conditions and developmentSmuggling and traffickingState and local government operationsTelephone and wireless communicationTrade restrictionsU.S. territories and protectorates

STOP Fentanyl Act of 2021

USA117th CongressHR-2366| House 
| Updated: 10/19/2021
Support, Treatment, and Overdose Prevention of Fentanyl Act of 2021 or the STOP Fentanyl Act of 2021 This bill addresses data collection, treatment, harm reduction, and other issues related to substance misuse and addiction. It particularly focuses on opioids, fentanyl, and related substances. Specifically, the bill expands surveillance of fentanyl and related substances. This includes establishing a pilot program to screen for contaminants in illicit drugs and a grant program to collect data on fentanyl-involved overdoses. The bill also specifies requirements concerning the collection and use of information about drugs seized by law enforcement. Additionally, the bill establishes and modifies requirements to increase access to treatment and prevention services. For example, the Bureau of Prisons must make certain services, including medication-assisted treatments, available to individuals in its custody. The bill also repeals a provision that requires dependence on opioids for at least one year before an individual may be admitted to certain treatment programs; allows providers to prescribe medications to treat substance use disorders following a telehealth evaluation; creates grant programs for treatment and harm reduction activities; and addresses issues pertaining to opioid overdose reversal drugs. Furthermore, the bill limits civil and criminal liability under specified laws for individuals who administer opioid overdose reversal drugs to an individual who reasonably appears to be experiencing an overdose, as well as for individuals who seek medical attention for themselves or on behalf of another for a drug overdose. The bill also requires multiple reports, including a report by the Department of State on foreign sources of certain drugs.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 5, 2021
Introduced in House
Apr 5, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 13, 2021
Referred to the Subcommittee on Health.
Apr 29, 2021

Latest Companion Bill Action

S 117-1457
Introduced in Senate
Oct 19, 2021
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
  • April 5, 2021
    Introduced in House


  • April 5, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 13, 2021
    Referred to the Subcommittee on Health.


  • April 29, 2021

    Latest Companion Bill Action

    S 117-1457
    Introduced in Senate


  • October 19, 2021
    Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Ann M. Kuster

Ann M. Kuster

Democratic Representative

New Hampshire

Cosponsors (13)
Tim Ryan (Democratic)Lisa Blunt Rochester (Democratic)David J. Trone (Democratic)Jimmy Panetta (Democratic)Debbie Dingell (Democratic)Madeleine Dean (Democratic)Paul Tonko (Democratic)Don Bacon (Republican)Joseph D. Morelle (Democratic)Dean Phillips (Democratic)Theodore E. Deutch (Democratic)Peter Welch (Democratic)Teresa Leger Fernandez (Democratic)

Crime and Federal Government Surveillance Subcommittee, Health Subcommittee, Judiciary Committee, Energy and Commerce Committee

Health

Related Bills

  • S 117-1457: STOP Fentanyl Act of 2021
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
American SamoaCardiovascular and respiratory healthCivil actions and liabilityCongressional oversightCorporate finance and managementCorrectional facilities and imprisonmentCriminal investigation, prosecution, interrogationCriminal justice information and recordsCriminal procedure and sentencingCustoms enforcementDrug, alcohol, tobacco useDrug safety, medical device, and laboratory regulationDrug therapyDrug trafficking and controlled substancesEmergency medical services and trauma careFederal preemptionGovernment information and archivesGovernment studies and investigationsHealth care costs and insuranceHealth care coverage and accessHealth information and medical recordsHealth programs administration and fundingHealth promotion and preventive careHealth technology, devices, suppliesHIV/AIDSHome and outpatient careIndian social and development programsInfectious and parasitic diseasesInflation and pricesInternet and video servicesInternet, web applications, social mediaLaw enforcement administration and fundingLaw enforcement officersManufacturingMarketing and advertisingMedical researchMental healthMinority healthNorthern Mariana IslandsPerformance measurementPostal servicePrescription drugsResearch administration and fundingResearch and developmentRural conditions and developmentSmuggling and traffickingState and local government operationsTelephone and wireless communicationTrade restrictionsU.S. territories and protectorates